Wealthspring Capital’s Phoenix Biotech Acquisition Corp. Unit PBAXU Stock Holding History

Wealthspring Capital’s Portfolio PBAXU Stock Details PBAXU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-177,300	Closed	-$1.79M	–	287
2022 Q3	$1.79M	Sell	177,300 -33,480	-16%	-$338K	0.35%	74
2022 Q2	$2.12M	Sell	210,780 -49,030	-19%	-$494K	0.4%	54
2022 Q1	$2.61M	Sell	259,810 -3,230	-1%	-$32.6K	0.51%	34
2021 Q4	$2.65M	Buy	+263,040	New	+$2.66M	0.57%	31

Other funds holding PBAXU

YCM

Yakira Capital Management Westport, Connecticut $351M AUM 21.82% 1-Year Est. Return

FTUS

Flow Traders U.S. New York $2.43B AUM 44.44% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Wealthspring Capital's PBAXU Position: Q4 2022 in Review

Wealthspring Capital sold out of Phoenix Biotech Acquisition Corp. Unit (PBAXU) in Q4 2022, closing a stake of 177,300 shares — an estimated $1.79M sold.

Wealthspring Capital first reported a position in PBAXU in Q4 2021 and held it in 4 quarters. The position peaked at $2.65M in Q4 2021. 3 funds tracked by Wall St. Rank hold PBAXU as of Q4 2022.

Wealthspring Capital reported no remaining Phoenix Biotech Acquisition Corp. Unit position as of Q4 2022 after selling out during the quarter.
Wealthspring Capital sold 177,300 Phoenix Biotech Acquisition Corp. Unit shares in Q4 2022, an estimated $1.79M.
Wealthspring Capital first reported a position in Phoenix Biotech Acquisition Corp. Unit in Q4 2021 and held it in 4 quarters.
Wealthspring Capital's Phoenix Biotech Acquisition Corp. Unit position peaked at $2.65M in Q4 2021.
3 funds tracked by Wall St. Rank held Phoenix Biotech Acquisition Corp. Unit as of Q4 2022.

Based on Wealthspring Capital's 13F filing for Q4 2022, filed 8 Feb 2023.